| Budget Amount *help |
¥16,640,000 (Direct Cost: ¥12,800,000、Indirect Cost: ¥3,840,000)
Fiscal Year 2017: ¥5,720,000 (Direct Cost: ¥4,400,000、Indirect Cost: ¥1,320,000)
Fiscal Year 2016: ¥5,720,000 (Direct Cost: ¥4,400,000、Indirect Cost: ¥1,320,000)
Fiscal Year 2015: ¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
|
|---|
| Outline of Final Research Achievements |
Allergen-specific immunotherapy (AIT) is promising as a radical therapy for allergic diseases, and AIT is being accepted in food allergy. Currently, AIT is mainly performed by the subcutaneous injection (SCIT) which requires to visit a hospital for long time, and is difficult to continue the treatment for patients of children due to the injection pain. Thus, development of alternative administration route is required in AIT research field.
Skin has a high potential as a target site for AIT, because it not only function as a barrier to protect from foreign substances but also induces various immune responses. In the development of effective epicutaneous immunotherapy (EPIT), an device capable of efficiently delivering the allergen into the skin is indispensable.
In the present study, we acquired a proof-of-concept for the establishment of EPIT using allergen-containing hydrogel patch (HG). We also demonstrated our EPIT system was safe and effective in children with severe milk allergy.
|
